3-(α-Hydroxy-isopropyl)-1-methyl-pyrazol | 101012-40-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(α-Hydroxy-isopropyl)-1-methyl-pyrazol
• 英文别名: 2-(1-methyl-1H-pyrazol-3-yl)-propan-2-ol；2-(1-Methyl-1H-pyrazol-3-YL)propan-2-OL；2-(1-methylpyrazol-3-yl)propan-2-ol
• CAS: 101012-40-2
• 化学式: C₇H₁₂N₂O
• 分子量: 140.185
• InChiKey: KIICXRAZTXYPBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] PYRIDAZINE DERIVATIVES AS RORc MODULATORS<br/>[FR] DÉRIVÉS DE PYRIDAZINE EN TANT QUE MODULATEURS DE RORC
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016177686A1

  公开（公告）日：2016-11-10

  Compounds of formula (I): or pharmaceutical salts thereof, wherein m, n, A, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

  公式（I）的化合物：或其药用盐，其中m、n、A、R1、R2、R3、R4和R5的定义如本文所述。还公开了制备这些化合物的方法，并将这些化合物用于治疗炎症性疾病，如关节炎。
• COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES
  申请人：Wang Tao

  公开号：US20080119480A1

  公开（公告）日：2008-05-22

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

  该发明提供了具有药物和生物影响性质的化合物，它们的制药组合物和使用方法。特别地，该发明涉及氮杂吲哌酮乙酰基哌嗪衍生物。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药物、抗感染药物、免疫调节剂或HIV进入抑制剂联合使用。更具体地，本发明涉及治疗HIV和艾滋病。
• PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS
  申请人：Wang Tao

  公开号：US20100093752A1

  公开（公告）日：2010-04-15

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

  本发明提供了具有药物和生物影响性质的化合物，它们的药物组合物和使用方法。特别是，本发明涉及氮杂吲哚氧乙酰哌嗪衍生物。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药物、抗感染药物、免疫调节剂或HIV进入抑制剂结合使用。更具体地，本发明涉及治疗HIV和艾滋病。
• PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES
  申请人：Bristol-Myers Squibb Company

  公开号：US20150329543A1

  公开（公告）日：2015-11-19

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

  本发明提供具有药物和生物影响特性的化合物，其制药组合物和使用方法。特别地，本发明涉及氮杂吲哚氧乙酰基哌嗪衍生物。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药物、抗感染剂、免疫调节剂或HIV进入抑制剂联合使用。更具体地，本发明涉及治疗HIV和艾滋病。
• SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES
  申请人：Bristol-Myers Squibb Company

  公开号：US20150259342A1

  公开（公告）日：2015-09-17

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives having the Formula I: wherein Q is These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

  本发明提供了具有药物和生物影响性质的化合物，它们的制药组合物和使用方法。特别地，本发明涉及具有式I的氮杂吲哌酮乙酰基哌嗪衍生物，其中Q为。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药物、抗感染药物、免疫调节剂或HIV进入抑制剂联合使用。更具体地，本发明涉及治疗HIV和艾滋病。